Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NxThera, Inc.
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Medtech Insight recorded 17 merger or acquisition deals in March, a rise from the nine deals recorded last month and in the same period last year. It was a busy month for Boston Scientific, which racked up two acquisitions, paying $460m for urology device maker NxThera and an undisclosed price for endoscopy firm EMcision.
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive